2018

02/19/2018 David Hale joins the Guerbet Executive Committee as Chief Commercial Officer, Diagnostic Imaging

Villepinte (France), February 19, 2018 (08:00 CET) – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, has announced the appointment of David Hale as Chief Commercial Officer Diagnostic Imaging “We are delighted to welcome David as a new member...

[more]


02/15/2018 2017 revenue at constant exchange rates: €812.4 million; +4.7%

Villepinte, February 15, 2018 – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €807.1 million at December 31, 2017, up by 4.0% at current exchange rates. This growth includes a negative exchange rate effect* of €5.3...

[more]


01/08/2018 Guerbet announces its acquisition of Accurate Medical Therapeutics

Guerbet announces its acquisition of Accurate Medical Therapeutics, an innovative company that develops microcatheters for interventional radiology

[more]